Trials / Unknown
UnknownNCT06123455
Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer
A Prospective, Randomized Controlled Clinical Study of The Efficacy and Safety of Taurine Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy for Treatment of Advanced Gastric Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Tang-Du Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (sintilimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer patient outcomes than with sintilimab and chemotherapy alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Taurine | Taurine supplementation in capsules of 1.0 gram of taurine powder. Dosage: 2.0 gram/day. Frequency: 2 time/day. |
| BIOLOGICAL | Sintilimab | Sintilimab |
| DRUG | XELOX regimen | Oxaliplatin + capecitabine |
| DRUG | SOX regimen | Oxaliplatin + S-1 (tegafur/gimeracil/oteracil potassium) |
| DRUG | FOLFOX regimen | Oxaliplatin + leucovorin + fluorouracil |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2025-07-31
- Completion
- 2025-07-31
- First posted
- 2023-11-08
- Last updated
- 2023-11-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06123455. Inclusion in this directory is not an endorsement.